# Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

> **NCT04079738** · PHASE1,PHASE2 · TERMINATED · sponsor: **H Scott Boswell** · enrollment: 8 (actual)

## Conditions studied

- AML
- AML, Adult

## Interventions

- **DRUG:** TAK-659
- **DRUG:** Ixazomib

## Key facts

- **NCT ID:** NCT04079738
- **Lead sponsor:** H Scott Boswell
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-20
- **Primary completion:** 2021-09-22
- **Final completion:** 2022-02-23
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Funder requested termination due to halting internal development of TAK-659
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04079738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04079738, "Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04079738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*